These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 14612098

  • 1. Effect of daclizumab (zenapax) on prevention of acute rejection of renal transplantation.
    Poorrezagholi F, Einollahi B, Firoozan A, Nafar M, Yadegari H, Moghaddam SM, Simforoosh N, Basiri A, Farhangi S.
    Transplant Proc; 2003 Nov; 35(7):2735-6. PubMed ID: 14612098
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation.
    Vincenti F.
    Transplant Proc; 1999 Sep; 31(6):2206-7. PubMed ID: 10500546
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Use of daclizumab in the immunosuppression of high-risk kidney and kidney/pancreas recipients: Warsaw Transplantation Center experience.
    Baczkowska T, Kukula K, Nowacka-Cieciura E, Cieciura T, Lewandowska D, Ciecierski R, Grochowiecki T, Rowinski W, Szmidt J, Durlik M, Lao M.
    Transplant Proc; 2002 Mar; 34(2):551-2. PubMed ID: 12009620
    [No Abstract] [Full Text] [Related]

  • 8. Placebo-controlled study of a humanized anti-TAC monoclonal antibody in dual therapy for prevention of acute rejection after renal transplantation.
    Charpentier B, Thervet E.
    Transplant Proc; 1998 Jun; 30(4):1331-2. PubMed ID: 9636541
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Interleukin-2R antagonists in the prevention of acute rejection in living donor transplantation.
    Ivanovski N, Popov Z, Kolevski P, Cakalaroski K, Spasovski G, Sikole A, Paneva-Masin J.
    Transplant Proc; 2001 Jun; 33(7-8):3203-4. PubMed ID: 11750374
    [No Abstract] [Full Text] [Related]

  • 11. Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function.
    Bumgardner GL, Ramos E, Lin A, Vincenti F, Daclizumab Triple Therapy and Double Therapy Groups.
    Transplantation; 2001 Aug 27; 72(4):642-7. PubMed ID: 11544424
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.
    Burke GW, Ciancio C, Blomberg BB, Rosen A, Suzart K, Roth D, Kupin W, Esquenazi V, Miller J.
    Transplant Proc; 2002 Aug 27; 34(5):1610-1. PubMed ID: 12176505
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. IL-2 receptor blockers in liver transplantation: initial experience with daclizumab in Chile.
    Innocenti F, Humeres R, Zamboni M, Sanhueza E, Zapata R, Hepp J, Rius M.
    Transplant Proc; 2003 Nov 27; 35(7):2520-1. PubMed ID: 14612001
    [Abstract] [Full Text] [Related]

  • 18. Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group.
    Hengster P, Pescovitz MD, Hyatt D, Margreiter R.
    Transplantation; 1999 Jul 27; 68(2):310-3. PubMed ID: 10440409
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.